Chronic HBV infection in adults w/ evidence of active viral replication & either evidence of persistent elevations in serum aminotransferases (ALT/AST) or histologically active disease.
Should be taken on an empty stomach: For patients w/ decompensated liver disease & lamivudine-refractory patients w/ compensated liver disease, take 2 hr before or 2 hr after meals. In nucleoside-naive patients w/ compensated liver disease, may administer w/ meals if necessary.
Discontinue use if rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology occur. Not to be used for HIV/HBV co-infected patients not receiving highly active antiretroviral therapy. Not to be used to reduce risk of HBV transmission. Not recommended for HIV infection. Lactic acidosis associated w/ severe hepatomegaly & hepatic steatosis. Co-infection w/ hepatitis C or D; HIV w/ low CD4 cell counts (<200 cells/mm3). May affect ability to drive & use machines. Renal impairment. Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Ped & adolescents <16 yr.
J05AF10 - entecavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
